和黄医药(00013)：达唯珂(TAZVERIK)获纳入首版国家商业健康保险创新药品目录

Core Viewpoint - Hutchison China MediTech Limited (00013) announced the renewal of its medical insurance agreements with the National Healthcare Security Administration of China, ensuring the continued inclusion of ELUNATE®, ORPATHYS®, and SULANDA® in the updated National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List effective from January 1, 2026 [1] Group 1 - ELUNATE®, ORPATHYS®, and SULANDA® will remain included in the National Medical Insurance Drug List starting January 1, 2026 [1] - TAZVERIK® has been included in the inaugural National Commercial Health Insurance Innovative Drug List [1]